Ranked #1,485 of 8,699 institutional investors
Venrock Adviser, LLC
New York, NY
$2.07B
US stock portfolio at live prices · today +$37.3M (+1.83%)
Market closed. Prices as of Nov 20, 9:11 AM ET
- Value at quarter end (Q3 2026)
- $2.06B
- Change from Q2 2026
- −$1.24B (−37.59%)
- Positions
- 27 · 3 new, 2 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$157M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesORKA 19.5%ERAS 13.8%SYRE 11.7%KRSA 7.77%VRDN 4.94%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| ORKA Oruka Therapeutics, Inc. | 4,148,428 | $405M | 19.5% | Unchanged |
| ERAS Erasca, Inc. | 20,089,932 | $286M | 13.8% | Added +12% |
| SYRE Spyre Therapeutics, Inc. | 2,485,448 | $243M | 11.7% | Reduced −17% |
| KRSA Korsana Biosciences, Inc. | 4,549,585 | $161M | 7.77% | New |
| VRDN Viridian Therapeutics, Inc. | 3,257,917 | $102M | 4.94% | Unchanged |
| SVRA Savara Inc. | 19,568,534 | $102M | 4.91% | Added +33% |
| DNTH Dianthus Therapeutics, Inc. | 822,020 | $69.7M | 3.36% | Reduced −30% |
| OCUL Ocular Therapeutix, Inc. | 10,346,926 | $60.6M | 2.92% | Unchanged |
| VOR Vor Biopharma Inc. | 3,041,719 | $56.3M | 2.72% | Unchanged |
| MAZE Maze Therapeutics, Inc. | 1,545,616 | $50.1M | 2.42% | Reduced −4% |
| JBIO Jade Biosciences, Inc. | 3,220,364 | $48.5M | 2.34% | Unchanged |
| COGT Cogent Biosciences, Inc. | 1,642,166 | $45.6M | 2.20% | Unchanged |
| DYN Dyne Therapeutics, Inc. | 2,173,913 | $34.8M | 1.68% | Unchanged |
| QUIT Achieve Life Sciences, Inc. | 5,502,064 | $32.3M | 1.56% | Added +100% |
| ANL Adlai Nortye Group Ltd. | 3,212,731 | $29.1M | 1.40% | Unchanged |
| RLMD Relmada Therapeutics, Inc. | 7,445,050 | $23.2M | 1.12% | Added +9% |
| ADRX ADARx Pharmaceuticals, Inc. | 1,625,793 | $23.0M | 1.11% | New |
| ORIC ORIC Pharmaceuticals, Inc. | 2,944,056 | $22.7M | 1.09% | Reduced −32% |
| XFOR X4 Pharmaceuticals, Inc. | 7,644,072 | $22.6M | 1.09% | Added +295% |
| SRZN Surrozen, Inc. | 632,931 | $19.4M | 0.94% | Unchanged |
| PBLS Parabilis Medicines, Inc. | 625,000 | $17.3M | 0.83% | Unchanged |
| ANRO Alto Neuroscience Inc | 500,000 | $13.3M | 0.64% | Unchanged |
| ARVN Arvinas, Inc. | 1,952,533 | $13.2M | 0.63% | New |
| CGEM Cullinan Therapeutics, Inc. | 1,379,965 | $12.5M | 0.60% | Unchanged |
| IPSC Century Therapeutics, Inc. | 8,695,652 | $11.5M | 0.55% | Unchanged |
| ARTV Artiva Biotherapeutics, Inc. | 2,043,596 | $7.8M | 0.38% | Unchanged |
| KRRO Korro Bio, Inc. | 443,431 | $5.4M | 0.26% | Reduced −56% |